FDA Adverse Event Data Clouds Potential Fluoroquinolone Label Changes
Advisory committee unsure how to describe fluoroquinolone-associated disability in labeling.
You may also be interested in...
Risk of disabling, potentially permanent serious side effects that can occur together will be added to Cipro, Levaquin labels along with limitation against use for some self-limiting conditions unless there are no alternative treatments.
Overwhelming votes against existing labels for the antibiotics likely means sponsors and FDA have some safety planning to do.
Joint advisory committee meeting will discuss post-marketing safety data, including adverse events across organ systems.